Drug delivery and therapeutic impact of extended-release acetylsalicylic acid

Kevin P. Bliden, Jeff Patrick, Andrew T. Pennell, Udaya S. Tantry, Paul A. Gurbel

Research output: Contribution to journalArticle

Abstract

Current treatment guidelines recommend once-daily, low-dose acetylsalicylic acid (ASA; aspirin) for secondary prevention of cardiovascular events. However, the anti-thrombotic benefits of traditional ASA formulations may not extend over a 24-h period, especially in patients at high risk for a recurrent cardiovascular event. A next-generation, extended-release ASA formulation (ER-ASA) has been developed to provide 24-h anti-thrombotic coverage with once-daily dosing. The pharmacokinetics of ER-ASA indicates slower absorption and prolonged ASA release versus immediate-release ASA, with a favorable safety profile. ER-ASA minimizes systemic ASA absorption and provides sustained antiplatelet effects over a 24-h period.

Original languageEnglish (US)
Pages (from-to)45-58
Number of pages14
JournalFuture Cardiology
Volume12
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Aspirin
Secondary Prevention
Pharmaceutical Preparations
Pharmacokinetics
Guidelines
Safety
Therapeutics
Physiological Absorption

Keywords

  • acetylsalicylic acid
  • antiplatelet
  • cardiovascular disease
  • diabetes
  • Durlaza
  • extended-release
  • microcapsule
  • secondary prevention
  • thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Molecular Medicine

Cite this

Bliden, K. P., Patrick, J., Pennell, A. T., Tantry, U. S., & Gurbel, P. A. (2016). Drug delivery and therapeutic impact of extended-release acetylsalicylic acid. Future Cardiology, 12(1), 45-58. https://doi.org/10.2217/fca.15.60

Drug delivery and therapeutic impact of extended-release acetylsalicylic acid. / Bliden, Kevin P.; Patrick, Jeff; Pennell, Andrew T.; Tantry, Udaya S.; Gurbel, Paul A.

In: Future Cardiology, Vol. 12, No. 1, 01.01.2016, p. 45-58.

Research output: Contribution to journalArticle

Bliden, KP, Patrick, J, Pennell, AT, Tantry, US & Gurbel, PA 2016, 'Drug delivery and therapeutic impact of extended-release acetylsalicylic acid', Future Cardiology, vol. 12, no. 1, pp. 45-58. https://doi.org/10.2217/fca.15.60
Bliden, Kevin P. ; Patrick, Jeff ; Pennell, Andrew T. ; Tantry, Udaya S. ; Gurbel, Paul A. / Drug delivery and therapeutic impact of extended-release acetylsalicylic acid. In: Future Cardiology. 2016 ; Vol. 12, No. 1. pp. 45-58.
@article{12b4f99d3aeb498dad810da041d4f889,
title = "Drug delivery and therapeutic impact of extended-release acetylsalicylic acid",
abstract = "Current treatment guidelines recommend once-daily, low-dose acetylsalicylic acid (ASA; aspirin) for secondary prevention of cardiovascular events. However, the anti-thrombotic benefits of traditional ASA formulations may not extend over a 24-h period, especially in patients at high risk for a recurrent cardiovascular event. A next-generation, extended-release ASA formulation (ER-ASA) has been developed to provide 24-h anti-thrombotic coverage with once-daily dosing. The pharmacokinetics of ER-ASA indicates slower absorption and prolonged ASA release versus immediate-release ASA, with a favorable safety profile. ER-ASA minimizes systemic ASA absorption and provides sustained antiplatelet effects over a 24-h period.",
keywords = "acetylsalicylic acid, antiplatelet, cardiovascular disease, diabetes, Durlaza, extended-release, microcapsule, secondary prevention, thrombosis",
author = "Bliden, {Kevin P.} and Jeff Patrick and Pennell, {Andrew T.} and Tantry, {Udaya S.} and Gurbel, {Paul A.}",
year = "2016",
month = "1",
day = "1",
doi = "10.2217/fca.15.60",
language = "English (US)",
volume = "12",
pages = "45--58",
journal = "Future Cardiology",
issn = "1479-6678",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Drug delivery and therapeutic impact of extended-release acetylsalicylic acid

AU - Bliden, Kevin P.

AU - Patrick, Jeff

AU - Pennell, Andrew T.

AU - Tantry, Udaya S.

AU - Gurbel, Paul A.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Current treatment guidelines recommend once-daily, low-dose acetylsalicylic acid (ASA; aspirin) for secondary prevention of cardiovascular events. However, the anti-thrombotic benefits of traditional ASA formulations may not extend over a 24-h period, especially in patients at high risk for a recurrent cardiovascular event. A next-generation, extended-release ASA formulation (ER-ASA) has been developed to provide 24-h anti-thrombotic coverage with once-daily dosing. The pharmacokinetics of ER-ASA indicates slower absorption and prolonged ASA release versus immediate-release ASA, with a favorable safety profile. ER-ASA minimizes systemic ASA absorption and provides sustained antiplatelet effects over a 24-h period.

AB - Current treatment guidelines recommend once-daily, low-dose acetylsalicylic acid (ASA; aspirin) for secondary prevention of cardiovascular events. However, the anti-thrombotic benefits of traditional ASA formulations may not extend over a 24-h period, especially in patients at high risk for a recurrent cardiovascular event. A next-generation, extended-release ASA formulation (ER-ASA) has been developed to provide 24-h anti-thrombotic coverage with once-daily dosing. The pharmacokinetics of ER-ASA indicates slower absorption and prolonged ASA release versus immediate-release ASA, with a favorable safety profile. ER-ASA minimizes systemic ASA absorption and provides sustained antiplatelet effects over a 24-h period.

KW - acetylsalicylic acid

KW - antiplatelet

KW - cardiovascular disease

KW - diabetes

KW - Durlaza

KW - extended-release

KW - microcapsule

KW - secondary prevention

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84953279636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953279636&partnerID=8YFLogxK

U2 - 10.2217/fca.15.60

DO - 10.2217/fca.15.60

M3 - Article

VL - 12

SP - 45

EP - 58

JO - Future Cardiology

JF - Future Cardiology

SN - 1479-6678

IS - 1

ER -